# Curaleaf Holdings, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Curaleaf Holdings, Inc.).

## Overview

Curaleaf Holdings, Inc. is a cannabis company that cultivates, manufactures, distributes and sells medical and adult-use cannabis products through vertically integrated operations. Its portfolio includes flower, pre-rolls, vaporizer cartridges, edibles, concentrates, topicals, tinctures and beverages sold under brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, JAMS and Anthem. The company operates U.S. retail and wholesale businesses alongside an international medical-cannabis platform serving Europe and other overseas markets.

## Products & services

• Cannabis flower, pre-rolls and vaporizer cartridges
• Edibles, concentrates, topicals, tinctures and beverages
• Medical cannabis products and standardized preparations
• Curaleaf Que Medical Inhalation Device (QMID)
• Wholesale distribution and brand licensing
• Retail cannabis dispensaries

- **Inhalable cannabis products** (40%) — Flower, pre-rolls, vaporizer cartridges and medical inhalation products.
- **Edibles and consumables** (20%) — Edibles, beverages and other ingestible cannabis products.
- **Extracts and concentrates** (15%) — Cannabis concentrates, oils and related extraction-based products.
- **Topicals and tinctures** (10%) — Topical and liquid cannabis products for medical and adult-use consumers.
- **Wholesale and licensing** (15%) — Wholesale product distribution and asset-light brand licensing arrangements.

- Cannabis flower, pre-rolls and vaporizer cartridges
- Edibles, concentrates, topicals, tinctures and beverages
- Medical cannabis preparations for pharmacies and clinics
- Curaleaf Que Medical Inhalation Device (QMID)
- Wholesale distribution to licensed dispensaries
- Retail dispensary sales and brand licensing

## Customers

Curaleaf sells to adult-use consumers and medical cannabis patients through its own U.S. retail stores and other licensed dispensaries. Wholesale partners purchase branded products for resale across licensed retail networks, while international medical products reach patients through clinics, pharmacies and telemedicine platforms. Healthcare professionals, hospital pharmacies and medical-cannabis distributors are important channels for the company’s European operations, including standardized preparations in Spain.

- **U.S. adult-use consumers** (primary) — Purchase flower, vapes, edibles and other branded products through Curaleaf stores and licensed dispensaries.
- **U.S. medical cannabis patients** (primary) — Buy regulated cannabis products for therapeutic use through state-licensed retail channels.
- **Wholesale dispensary partners** (primary) — Purchase Curaleaf brands for resale, expanding distribution beyond company-operated retail stores.
- **International medical-cannabis channels** (secondary) — Clinics, pharmacies and telemedicine platforms distribute Curaleaf medical products to patients.
- **Healthcare and hospital pharmacy partners** (emerging) — Support access to standardized cannabis preparations in emerging regulated medical markets.

- Adult-use consumers buying branded cannabis through licensed retailers
- Medical patients seeking standardized cannabis treatments
- Licensed dispensaries purchasing wholesale branded products
- Clinics, pharmacies and telemedicine platforms distributing medical products
- Hospital pharmacies and healthcare partners serving regulated markets

## Geography

The United States is Curaleaf’s core operating market, with company-owned cultivation, manufacturing and retail infrastructure. The company reported second-quarter 2026 international revenue of $51 million against total revenue of $340 million, implying an estimated 15% international contribution, while U.S. operations represented approximately 85%. Curaleaf International distributes through European clinics, pharmacies and telemedicine platforms and also maintains distribution links across Canada and Australasia.

- **United States** (85%) — Estimated as the remainder of Q2 2026 revenue after reported international revenue of $51 million out of $340 million total.
- **International** (15%) — Based on reported Q2 2026 international revenue of $51 million; includes Europe, Canada and Australasia.

- U.S. operations include cultivation, manufacturing and branded retail stores
- Estimated U.S. share was approximately 85% of Q2 2026 revenue
- International revenue was $51 million in Q2 2026
- Europe is served through clinics, pharmacies and telemedicine platforms
- Canada and Australasia extend the international distribution network

## Strategy

Curaleaf’s strategy combines brand building, customer-focused product assortment and operational control across cultivation, manufacturing, retail and distribution. The company is expanding wholesale relationships, asset-light licensing and international medical-cannabis channels to increase market access without relying exclusively on owned retail infrastructure. Its European platform emphasizes regulated medical products, scientific research and specialized technologies such as the QMID inhalation device.

- **Strengthen branded product platforms** (medium-term) — Distinctive brands and broad price points can improve consumer retention and retail shelf access.
- **Expand wholesale distribution** (short-term) — Wholesale relationships increase product reach across licensed dispensaries beyond owned stores.
- **Scale international medical cannabis** (medium-term) — European medical markets provide an avenue for regulated cross-border growth and specialized products.
- **Use asset-light market access** (medium-term) — Brand licensing and third-party distribution can broaden reach while moderating capital requirements.

- Build differentiated cannabis brands across price and product tiers
- Increase wholesale distribution through licensed retail partners
- Use owned cultivation and manufacturing to control supply quality
- Expand European medical-cannabis access through regulated channels
- Apply licensing to extend brands with lower capital intensity
- Develop science-led products such as the QMID inhaler

## Risks

Curaleaf operates in a heavily regulated industry where U.S. federal cannabis restrictions, state licensing requirements and evolving international rules can limit market access and financial services. Its TSX listing imposes additional constraints on investments and fund transfers involving U.S. cannabis operations, while exchange and clearing restrictions could affect shareholder liquidity. Competition from illicit operators, other multistate operators, adjacent consumer categories and licensed international producers can pressure pricing, brand share and utilization of the company’s vertically integrated assets.

- **U.S. federal and state regulatory uncertainty** [critical] — Changes in enforcement, licensing or cannabis classification can restrict operations, investment and market access.
- **TSX listing compliance constraints** [high] — TSX requirements limit certain investments and fund transfers involving U.S. cannabis activities; noncompliance could threaten listing status.
- **Limited financial-services access** [high] — Cannabis-related banking and financing restrictions can constrain liquidity, borrowing and growth investment.
- **Illicit-market competition** [high] — Unlicensed sellers avoid regulatory, compliance and tax burdens, enabling lower prices and potentially reducing legal-market demand.
- **Intensifying legal-market competition** [medium] — Multistate operators, small producers, cannabinoid companies and adjacent consumer categories compete on price, quality and distribution.

- Federal and state cannabis rules can restrict operations and investment
- TSX requirements limit certain U.S. cannabis ownership and fund transfers
- Banking and financing access remains constrained for U.S. cannabis firms
- Illicit-market operators compete without comparable taxes or compliance costs
- Wholesale mix can reduce margins versus company-owned retail sales
- Regulatory shifts may change medical, adult-use and tax treatment

## Accounting

Curaleaf prepares its financial statements under U.S. GAAP, with reported results affected by inventory costing, product mix and the timing of retail versus wholesale sales. Cannabis regulation creates significant tax and compliance judgment, including uncertainty over the applicability of Section 280E to medical and adult-use operations. The company also has exposure to impairment estimates, leases, consolidation of controlled entities and valuation of acquired intangible assets, all of which can materially affect reported earnings and asset values.

- **Revenue recognition and channel mix** — Revenue and gross margin volatility
- **Inventory valuation** — Cost of goods sold, inventory and gross profit
- **Cannabis tax treatment** — Income tax expense, deferred taxes and operating cash flow
- **Goodwill and intangible asset impairment** — Operating income and asset carrying values
- **Leases and consolidation** — Assets, liabilities, depreciation and operating expenses

- Retail and wholesale revenue is generally recognized when products are delivered
- Wholesale mix affects cost of goods sold and reported gross margin
- Inventory costing and write-downs affect gross profit and working capital
- Section 280E treatment can materially affect tax expense and cash taxes
- Goodwill and intangible impairment depend on market and operating forecasts
- Leases and consolidation judgments affect liabilities and operating assets

---

*Last updated: 2026-09-24T12:17:26.038405+00:00*